The G-BA starts the development of a new DMP for obesity
This new DMP for obesity should consider and combine various therapeutic approaches to offer the best possible care, treat patients with obesity
Tag: G-BA
NUB method assessments to become faster
Early benefit assessments are completed within 12 months, while method assessments used to take around 3 years. In 2020, the G-BA introduced
The early benefit assessment – 7 new laws since AMNOG
Since 2011, 7 new laws were added to AMNOG to dictate the early benefit assessment of drugs. Therefore, it is often called
G-BA assessment of CAR-T therapy Tecartus
The G-BA has now completed its benefit assessment of the CAR-T therapy, Tecartus, which is indicated for the treatment of mantle cell
G-BA assessments of new indications
The AMNOG law dictates that every pharmaceutical product with a new chemical entity which received its marketing authorization on or after 1